Instead of focusing on biological age markers, longevity research should prioritize 'hard outcomes' like actual death rates, cancer rates, and cardiovascular disease rates.

Medical evidence has a hierarchy, with self-experimentation case studies at the bottom and large randomized clinical trials and systematic reviews at the top, which should be the basis for clinical recommendations.

Funding for human clinical trials on Rapamycin is difficult to secure because the drug cannot be patented, offering no financial incentive for pharmaceutical companies.

Rapamycin has a significant risk profile as it suppresses the immune system and specifically the natural killer (NK) cells that fight cancer, making the dosage extremely important.

The Interventions Testing Program (ITP) provides highly reliable preclinical data on drugs like Rapamycin because it runs the same experiment in three separate labs simultaneously to ensure the results are reproducible.

Biological age test kits are interesting research tools, but they are not clinically validated to predict health outcomes like cancer or death and shouldn't be used to make personal health decisions.

The form of Rapamycin used is critical, as Sirolimus is more selective for the mTORC1 pathway, while Everolimus targets both mTORC1 and mTORC2, the latter of which is linked to more side effects.